- Home
- EBON vs SCYX Comparison
EBON vs SCYX Comparison
Compare EBON & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBON
- SCYX
- Stock Information
- Founded
- EBON 2010
- SCYX 1999
- Country
- EBON China
- SCYX United States
- Employees
- EBON N/A
- SCYX N/A
- Industry
- EBON Semiconductors
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- EBON Technology
- SCYX Health Care
- Exchange
- EBON Nasdaq
- SCYX Nasdaq
- Market Cap
- EBON 25.3M
- SCYX 28.5M
- IPO Year
- EBON 2020
- SCYX 2014
- Fundamental
- Price
- EBON $4.85
- SCYX $0.74
- Analyst Decision
- EBON
- SCYX
- Analyst Count
- EBON 0
- SCYX 0
- Target Price
- EBON N/A
- SCYX N/A
- AVG Volume (30 Days)
- EBON 34.4K
- SCYX 188.8K
- Earning Date
- EBON 08-22-2025
- SCYX 08-07-2025
- Dividend Yield
- EBON N/A
- SCYX N/A
- EPS Growth
- EBON N/A
- SCYX N/A
- EPS
- EBON N/A
- SCYX N/A
- Revenue
- EBON $5,868,771.00
- SCYX $2,630,000.00
- Revenue This Year
- EBON N/A
- SCYX $410.22
- Revenue Next Year
- EBON N/A
- SCYX $248.83
- P/E Ratio
- EBON N/A
- SCYX N/A
- Revenue Growth
- EBON 20.88
- SCYX N/A
- 52 Week Low
- EBON $3.00
- SCYX $0.66
- 52 Week High
- EBON $10.94
- SCYX $2.28
- Technical
- Relative Strength Index (RSI)
- EBON 70.33
- SCYX 46.93
- Support Level
- EBON $4.67
- SCYX $0.67
- Resistance Level
- EBON $5.40
- SCYX $0.83
- Average True Range (ATR)
- EBON 0.35
- SCYX 0.05
- MACD
- EBON 0.17
- SCYX 0.01
- Stochastic Oscillator
- EBON 77.14
- SCYX 47.06
About EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.